Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Dacomitinib |
Trade Name | Vizimpro |
Synonyms | PF-00299804|PF299804 |
Drug Descriptions |
Vizimpro (dacomitinib) is a second-generation EGFR inhibitor and pan-HER inhibitor that inhibits HER2 and multiple EGFR subtypes including EGFR T790M, resulting in decreased proliferation and increased apoptosis in EGFR-expressing and HER2-expressing tumor cells (PMID: 22761403, PMID: 18606718). Vizimpro (dacomitinib) is FDA approved for use in patients with metastatic non-small cell lung cancer with EGFR exon 19 deletion or L858R mutation as first-line treatment (FDA.gov). |
DrugClasses | EGFR Inhibitor 2nd gen 3 HER inhibitor (Pan) 6 |
CAS Registry Number | 1110813-31-4 |
NCIT ID | C53398 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Anlotinib + Dacomitinib + Olaparib + Pemetrexed Disodium + Temozolomide | Anlotinib Dacomitinib Olaparib Pemetrexed Disodium Temozolomide | 0 | 0 |
BMS-754807 + Dacomitinib | BMS-754807 Dacomitinib | 0 | 0 |
Crizotinib + Dacomitinib | Crizotinib Dacomitinib | 0 | 0 |
Dacomitinib | Dacomitinib | 0 | 7 |
Dacomitinib + Gedatolisib | Dacomitinib Gedatolisib | 0 | 1 |
Dacomitinib + Osimertinib | Dacomitinib Osimertinib | 0 | 1 |
Dacomitinib + PD-0325901 | Dacomitinib PD-0325901 | 0 | 0 |
Dacomitinib + Selumetinib | Dacomitinib Selumetinib | 0 | 0 |